tradingkey.logo

BRIEF-Alloy Therapeutics Announces Target Specific Collaboration & License Agreement For Use Of Anticlastic Antisense Platform With Sanofi

ReutersJan 7, 2025 4:07 PM

- ALLOY THERAPEUTICS:

  • ALLOY THERAPEUTICS: ANNOUNCES A TARGET SPECIFIC COLLABORATION & LICENSE AGREEMENT FOR USE OF ANTICLASTIC ANTISENSE PLATFORM WITH SANOFI

  • ALLOY THERAPEUTICS: SANOFI TO PROVIDE ALLOY WITH UPFRONT LICENSE FEES & NEAR-TERM PRECLINICAL MILESTONE PAYMENTS UP TO $27.5 MILLION

  • ALLOY THERAPEUTICS: UNDER AGREEMENT, ALLOY ALSO ELIGIBLE TO RECEIVE DISCOVERY, DEVELOPMENT, AND COMMERCIAL MILESTONE PAYMENTS OF OVER $400 MILLION

Source text: ID:nBw3F9qb7a

Further company coverage: SASY.PA

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Related Articles